ALPM.Y Stock Overview
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Astellas Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥9.90 |
| 52 Week High | JP¥16.91 |
| 52 Week Low | JP¥9.15 |
| Beta | 0.29 |
| 1 Month Change | -5.44% |
| 3 Month Change | -8.25% |
| 1 Year Change | -36.56% |
| 3 Year Change | -35.12% |
| 5 Year Change | -28.41% |
| Change since IPO | 34.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALPM.Y | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.7% | 1.4% | 2.7% |
| 1Y | -36.6% | 12.9% | 26.0% |
Return vs Industry: ALPM.Y underperformed the US Pharmaceuticals industry which returned 12% over the past year.
Return vs Market: ALPM.Y underperformed the US Market which returned 25% over the past year.
Price Volatility
| ALPM.Y volatility | |
|---|---|
| ALPM.Y Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALPM.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: ALPM.Y's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 14,484 | Naoki Okamura | www.astellas.com |
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.
Astellas Pharma Inc. Fundamentals Summary
| ALPM.Y fundamental statistics | |
|---|---|
| Market cap | US$17.78b |
| Earnings (TTM) | US$109.66m |
| Revenue (TTM) | US$10.32b |
162.1x
P/E Ratio1.7x
P/S RatioIs ALPM.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALPM.Y income statement (TTM) | |
|---|---|
| Revenue | JP¥1.60t |
| Cost of Revenue | JP¥292.49b |
| Gross Profit | JP¥1.31t |
| Other Expenses | JP¥1.29t |
| Earnings | JP¥17.05b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.51 |
| Gross Margin | 81.76% |
| Net Profit Margin | 1.06% |
| Debt/Equity Ratio | 57.6% |
How did ALPM.Y perform over the long term?
See historical performance and comparison